<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum></forum>
<forum_title></forum_title>
<discussion_title>Illumina, Inc. (ILMN) Lifted to Strong-Buy at Vetr Inc. - Financial Market News</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://www.financial-market-news.com/illumina-inc-ilmn-lifted-to-strong-buy-at-vetr-inc/1066515/</topic_url>
<topic_text>
Filed Under: Analyst Articles - US - Markets 
Vetr upgraded shares of Illumina, Inc. (NASDAQ:ILMN) from a hold rating to a strong-buy rating in a research report report published on Wednesday morning, ARN reports. The firm currently has $174.52 price objective on the life sciences company’s stock. 
In other news, EVP Omead Ostadan sold 1,108 shares of the business’s stock in a transaction on Monday, February 1st. The shares were sold at an average price of $156.73, for a total value of $173,656.84. Following the sale, the executive vice president now owns 46,476 shares in the company, valued at approximately $7,284,183.48. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website . Also, CEO Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction on Tuesday, January 26th. The shares were sold at an average price of $171.70, for a total transaction of $3,434,000.00. Following the completion of the sale, the chief executive officer now owns 433,423 shares in the company, valued at approximately $74,418,729.10. The disclosure for this sale can be found here . 
Other hedge funds and institutional investors have added to or reduced their stakes in the company. Forte Capital LLC ADV boosted its position in Illumina by 0.6% in the first quarter. Forte Capital LLC ADV now owns 2,365 shares of the life sciences company’s stock worth $383,000 after buying an additional 15 shares in the last quarter. Moors &amp; Cabot Inc. boosted its position in Illumina by 0.6% in the fourth quarter. Moors &amp; Cabot Inc. now owns 6,818 shares of the life sciences company’s stock worth $1,309,000 after buying an additional 44 shares in the last quarter. Evercore Wealth Management LLC boosted its position in Illumina by 1.0% in the fourth quarter. Evercore Wealth Management LLC now owns 9,950 shares of the life sciences company’s stock worth $1,910,000 after buying an additional 100 shares in the last quarter. Nelson Roberts Investment Advisors LLC boosted its position in Illumina by 0.6% in the fourth quarter. Nelson Roberts Investment Advisors LLC now owns 20,105 shares of the life sciences company’s stock worth $3,859,000 after buying an additional 110 shares in the last quarter. Finally, Boston Advisors boosted its position in Illumina by 2.2% in the fourth quarter. Boston Advisors now owns 5,930 shares of the life sciences company’s stock worth $1,138,000 after buying an additional 125 shares in the last quarter. 
Several other analysts also recently issued reports on ILMN. Robert W. Baird reaffirmed a hold rating on shares of Illumina in a report on Tuesday, April 19th. Canaccord Genuity reissued a hold rating and issued a $160.00 price objective on shares of Illumina in a research report on Wednesday, March 9th. Leerink Swann reissued a market perform rating and issued a $165.00 price objective (down previously from $175.00) on shares of Illumina in a research report on Tuesday, April 19th. BTIG Research reissued a hold rating on shares of Illumina in a research report on Tuesday, April 19th. Finally, Piper Jaffray reissued a buy rating on shares of Illumina in a research report on Tuesday, April 19th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $174.74. 
Shares of Illumina ( NASDAQ:ILMN ) traded down 0.45% during trading on Wednesday, reaching $142.95. The company’s stock had a trading volume of 1,289,297 shares. Illumina has a 12-month low of $130.00 and a 12-month high of $242.37. The company has a market cap of $20.87 billion and a PE ratio of 46.11. The company has a 50 day moving average of $158.51 and a 200 day moving average of $161.84. 
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, February 2nd. The life sciences company reported $0.70 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.82 by $0.12. The business had revenue of $591.50 million for the quarter, compared to the consensus estimate of $576.39 million. During the same quarter in the previous year, the business earned $0.87 earnings per share. Illumina’s quarterly revenue was up 15.5% on a year-over-year basis. On average, analysts anticipate that Illumina will post $3.49 EPS for the current fiscal year. 
Illumina, Inc is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. 
To view Vetr’s full report, visit Vetr’s official website . Receive News &amp; Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts&apos; ratings for Illumina Inc. and related companies with MarketBeat.com&apos;s FREE daily email newsletter . Comment on this Post 
</topic_text>
<spam_score>0.00</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://www.financial-market-news.com/illumina-inc-ilmn-lifted-to-strong-buy-at-vetr-inc/1066515/</post_url>
<post_date>20160425</post_date>
<post_time></post_time>
<username>Mark Watkins</username>
<post>
Filed Under: Analyst Articles - US - Markets 
Vetr upgraded shares of Illumina, Inc. (NASDAQ:ILMN) from a hold rating to a strong-buy rating in a research report report published on Wednesday morning, ARN reports. The firm currently has $174.52 price objective on the life sciences company’s stock. 
In other news, EVP Omead Ostadan sold 1,108 shares of the business’s stock in a transaction on Monday, February 1st. The shares were sold at an average price of $156.73, for a total value of $173,656.84. Following the sale, the executive vice president now owns 46,476 shares in the company, valued at approximately $7,284,183.48. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website . Also, CEO Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction on Tuesday, January 26th. The shares were sold at an average price of $171.70, for a total transaction of $3,434,000.00. Following the completion of the sale, the chief executive officer now owns 433,423 shares in the company, valued at approximately $74,418,729.10. The disclosure for this sale can be found here . 
Other hedge funds and institutional investors have added to or reduced their stakes in the company. Forte Capital LLC ADV boosted its position in Illumina by 0.6% in the first quarter. Forte Capital LLC ADV now owns 2,365 shares of the life sciences company’s stock worth $383,000 after buying an additional 15 shares in the last quarter. Moors &amp; Cabot Inc. boosted its position in Illumina by 0.6% in the fourth quarter. Moors &amp; Cabot Inc. now owns 6,818 shares of the life sciences company’s stock worth $1,309,000 after buying an additional 44 shares in the last quarter. Evercore Wealth Management LLC boosted its position in Illumina by 1.0% in the fourth quarter. Evercore Wealth Management LLC now owns 9,950 shares of the life sciences company’s stock worth $1,910,000 after buying an additional 100 shares in the last quarter. Nelson Roberts Investment Advisors LLC boosted its position in Illumina by 0.6% in the fourth quarter. Nelson Roberts Investment Advisors LLC now owns 20,105 shares of the life sciences company’s stock worth $3,859,000 after buying an additional 110 shares in the last quarter. Finally, Boston Advisors boosted its position in Illumina by 2.2% in the fourth quarter. Boston Advisors now owns 5,930 shares of the life sciences company’s stock worth $1,138,000 after buying an additional 125 shares in the last quarter. 
Several other analysts also recently issued reports on ILMN. Robert W. Baird reaffirmed a hold rating on shares of Illumina in a report on Tuesday, April 19th. Canaccord Genuity reissued a hold rating and issued a $160.00 price objective on shares of Illumina in a research report on Wednesday, March 9th. Leerink Swann reissued a market perform rating and issued a $165.00 price objective (down previously from $175.00) on shares of Illumina in a research report on Tuesday, April 19th. BTIG Research reissued a hold rating on shares of Illumina in a research report on Tuesday, April 19th. Finally, Piper Jaffray reissued a buy rating on shares of Illumina in a research report on Tuesday, April 19th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $174.74. 
Shares of Illumina ( NASDAQ:ILMN ) traded down 0.45% during trading on Wednesday, reaching $142.95. The company’s stock had a trading volume of 1,289,297 shares. Illumina has a 12-month low of $130.00 and a 12-month high of $242.37. The company has a market cap of $20.87 billion and a PE ratio of 46.11. The company has a 50 day moving average of $158.51 and a 200 day moving average of $161.84. 
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, February 2nd. The life sciences company reported $0.70 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.82 by $0.12. The business had revenue of $591.50 million for the quarter, compared to the consensus estimate of $576.39 million. During the same quarter in the previous year, the business earned $0.87 earnings per share. Illumina’s quarterly revenue was up 15.5% on a year-over-year basis. On average, analysts anticipate that Illumina will post $3.49 EPS for the current fiscal year. 
Illumina, Inc is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. 
To view Vetr’s full report, visit Vetr’s official website . Receive News &amp; Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts&apos; ratings for Illumina Inc. and related companies with MarketBeat.com&apos;s FREE daily email newsletter . Comment on this Post 
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>US</country>
<main_image>http://www.financial-market-news.com/logos/IlluminaLogo.jpg</main_image>
</document>
